Clinical Trial Update: Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LMB-100 in combination with SEL-110 for mesothelioma has been terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peritoneal Mesothelioma
• Malignant Pleural Mesothelioma

Drugs mentioned

• LMB-100 (mesothelin-targeted immunotoxin)
• SEL-110

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma | Phase 1 | Status: TERMINATED | Results posted: 2019-11-22